Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

TXG


Top 10 Correlated ETFs

TXG


Top 10 Correlated Stocks

TXG


In the News

06:16 04 Oct 2022 TXG

Should You Buy the Nasdaq's 10 Worst-Performing 2022 Stocks?

The best performer on this list has lost three-fourths of its value this year.

04:05 04 Oct 2022 TXG

10x Genomics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

PLEASANTON, Calif. , Sept. 2, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the company will be participating in the upcoming Morgan Stanley 20th Annual Global Healthcare Conference in New York, New York.

08:49 04 Oct 2022 TXG

10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q2 2022 Results - Earnings Call Transcript

10x Genomics, Inc. (NASDAQ:TXG ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Cassie Corneau - Investor Relations and Strategic Finance Serge Saxonov - Chief Executive Officer & Co-founder Jim Wilbur - Chief Commercial Officer Justin McAnear - Chief Financial Officer Conference Call Participants Matt Sykes - Goldman Sachs Michael Ryskin - Bank of America Daniel Arias - Stifel Tejas Savant - Morgan Stanley Patrick Donnelly - Citi Daniel Brennan - Cowen Julia Qin - JP Morgan Matthew Larew - William Blair Kyle Mikson - Canaccord Genuity Operator Good afternoon. Thank you for attending the 10x Genomics Second Quarter Earnings Call.

08:20 04 Oct 2022 TXG

10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates

10x Genomics (TXG) delivered earnings and revenue surprises of -42.50% and 0.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

11:10 04 Oct 2022 TXG

Torex Gold Resources' (TORXF) CEO Jody Kuzenko on Q2 2022 Results - Earnings Call Transcript

Torex Gold Resources, Inc. (OTCPK:TORXF) Q2 2022 Earnings Conference Call August 4, 2022 9:00 AM ET Company Participants Dan Rollins - SVP, Corporate Development & IR Jody Kuzenko - President & CEO Andrew Snowden - CFO Dave Stefanuto - EVP, Technical Services & Capital Projects Conference Call Participants Trevor Turnbull - Scotia Capital Wayne Lam - RBC Capital markets Don DeMarco - National Bank Financial Operator Thank you for standing by. This is the conference operator.

11:37 04 Oct 2022 TXG

Analysts Estimate 10x Genomics (TXG) to Report a Decline in Earnings: What to Look Out for

10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

12:23 04 Oct 2022 TXG

Cytek Biosciences Vs. 10x Genomics: 2 Opposing Cell Visualization Investments

Cytek and 10x Genomics both offer single cell visualization tools, a growing and important field in modern medicine. However, each company sees huge differences in popularity, financial performance, and valuation, leading to a significant difference in outlook.

11:09 04 Oct 2022 TXG

10x Genomics stock suffering record drop toward record low after revenue warnings prompts downgrade

Shares of 10x Genomics Inc. TGX, -4.32% plunged 22.3% in active morning trading Friday, putting them on track to suffer a record one-day drop to a record low Friday, after the biotechnology company's revenue warning prompted BofA Securities analyst Derik de Bruin to turn bearish. Trading volume was 3.9 million shares, already about triple the full-day average of about 1.3 million shares.

05:03 04 Oct 2022 TXG

10X Genomics Reports Q2 Preliminary Revenues, Shares Plummet On Missing Street Expectation

10X Genomics Inc (NASDAQ: TXG) reported preliminary second-quarter revenue is expected to be ~$114.5 million, a decrease of 1% year-over-year, below the consensus of $127.7 million. The company sees America's revenue of ~$70.9 million (+8% Y/Y), EMEA ~$25.6 million (-11% Y/Y),.

04:31 04 Oct 2022 TXG

10x Genomics stock falls as revenue forecast disappoints

Shares of 10x Genomics Inc. TXG, -7.74% fell in the extended session Thursday after the biotech company said it expects second-quarter revenue to come in below Wall Street expectations. 10x Genomics shares dropped 15% after hours, following a 7.7% drop in the regular session to close at $43.29.

Financial details

Company Rating
Buy
Market Cap
3.24B
Income
-142.49M
Revenue
497.93M
Book val./share
6.9
Cash/share
4.4
Dividend
-
Dividend %
-
Employees
1.24K
Optionable
No
Shortable
Yes
Earnings
01 Nov 2022
P/E
-22.7
Forward P/E
-26.58
PEG
2.97
P/S
6.5
P/B
4.13
P/C
6.46
P/FCF
-20.04
Quick Ratio
4.88
Current Ratio
5.65
Debt / Equity
0.12
LT Debt / Equity
0.12
-
-
EPS (TTM)
-1.26
EPS next Y
-1.07
EPS next Q
-0.04
EPS this Y
-89.28%
EPS next Y
-15.08%
EPS next 5Y
-15.08%
EPS last 5Y
20.52%
Revenue last 5Y
47.15%
Revenue Q/Q
0.1%
EPS Q/Q
50%
-
-
-
-
SMA20
-14.71%
SMA50
-23.68%
SMA100
-39.58%
Inst Own
75.43%
Inst Trans
1.17%
ROA
-14%
ROE
-18%
ROC
-0.15%
Gross Margin
79%
Oper. Margin
-27%
Profit Margin
-29%
Payout
-
Shs Outstand
95.05M
Shs Float
92.65M
-
-
-
-
Target Price
-
52W Range
28.21-187.85
52W High
-84.79%
52W Low
+1.57%
RSI
39
Rel Volume
0.39
Avg Volume
1.37M
Volume
534.74K
Perf Week
-2.34%
Perf Month
-21.74%
Perf Quarter
-60.8%
Perf Half Y
-64.94%
-
-
-
-
Beta
1.70434
-
-
Volatility
1.06%, 2.77%
Prev Close
-0.14%
Price
28.44
Change
-4.47%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2019-12-312020-12-31 2021-12-31
Revenue per share
6.292.954.85
Net income per share
-0.8-5.37-0.58
Operating cash flow per share
0.89-2.15-0.21
Free cash flow per share
-0.21-2.53-1.21
Cash per share
10.856.565.81
Book value per share
10.757.318.08
Tangible book value per share
10.757.097.79
Share holders equity per share
10.757.318.08
Interest debt per share
0.840.640.82
Market cap
3.66B17.31B8.84B
Enterprise value
3.26B16.71B8.34B
P/E ratio
-117.02-31.9-151.84
Price to sales ratio
14.8757.9318.02
POCF ratio
105.61-79.45-413.64
PFCF ratio
-449.26-67.55-72.08
P/B Ratio
8.7123.4210.81
PTB ratio
8.7123.4210.81
EV to sales
13.2755.9216.99
Enterprise value over EBITDA
-156.19-32.53-338.9
EV to operating cash flow
94.22-76.69-389.99
EV to free cash flow
-400.8-65.2-67.96
Earnings yield
-0.01-0.03-0.01
Free cash flow yield
0-0.01-0.01
Debt to equity
0.050.080.09
Debt to assets
0.310.20.2
Net debt to EBITDA
18.881.1720.55
Current ratio
7.636.566.77
Interest coverage
-9.93-317.56-60.34
Income quality
-1.110.40.37
Dividend Yield
000
Payout ratio
000
Sales general and administrative to revenue
000
Research and developement to revenue
0.340.410.43
Intangibles to total assets
00.020.03
Capex to operating cash flow
-1.240.184.74
Capex to revenue
-0.17-0.13-0.21
Capex to depreciation
-6.05-2.02-3.58
Stock based compensation to revenue
0.050.160.2
Graham number
13.929.710.23
ROIC
-0.06-0.66-0.06
Return on tangible assets
-0.05-0.6-0.06
Graham Net
6.935.214.75
Working capital
417.79M656.24M637.23M
Tangible asset value
0716.72M787.66M
Net current asset value
295M584.1M546.33M
Invested capital
0.070.090.1
Average receivables
42.29M51.21M68.23M
Average payables
8.87M4.71M11.03M
Average inventory
22.61M29.96M44.96M
Days sales outstanding
49.5462.5463.44
Days payables outstanding
77.9129.485.48
Days of inventory on hand
91.32187.03295.41
Receivables turnover
7.375.845.75
Payables turnover
4.6812.424.27
Inventory turnover
41.951.24
ROE
-0.07-0.73-0.07
Capex per share
-1.09-0.38-1

Quarterly Fundamentals Overview

Last date of statement is 2022-06-30 for Q2

Metric History 2021-06-302021-09-302021-12-312022-03-31 2022-06-30
Revenue per share
1.051.131.281.011.01
Net income per share
-0.1-0.15-0.16-0.38-0.57
Operating cash flow per share
0.03-0.240.05-0.18-0.15
Free cash flow per share
-0.1-0.42-0.19-0.43-0.39
Cash per share
5.665.425.254.774.4
Book value per share
7.147.227.317.146.9
Tangible book value per share
6.866.947.046.886.65
Share holders equity per share
7.147.227.317.146.9
Interest debt per share
0.650.730.730.90.87
Market cap
21.51B16.14B16.67B8.59B5.14B
Enterprise value
20.96B15.62B16.16B8.38B4.96B
P/E ratio
-486.65-235-225.87-50.65-19.93
Price to sales ratio
185.72128.82116.1375.0544.84
POCF ratio
6.9K-615.72.87K-413.1-302.97
PFCF ratio
-1.88K-347.55-764.14-175.6-116.32
P/B Ratio
27.4220.1720.3910.656.56
PTB ratio
27.4220.1720.3910.656.56
EV to sales
180.96124.67112.6173.2143.31
Enterprise value over EBITDA
-8.18K-1.71K-1.91K-249.53-89.8
EV to operating cash flow
6.72K-595.852.78K-402.94-292.64
EV to free cash flow
-1.83K-336.34-740.96-171.28-112.36
Earnings yield
0000-0.01
Free cash flow yield
000-0.01-0.01
Debt to equity
0.080.090.090.120.12
Debt to assets
0.20.190.20.20.22
Net debt to EBITDA
215.1256.8359.86.293.17
Current ratio
6.697.416.777.385.65
Interest coverage
-49.42-72.51-72.95-326.05-579.06
Income quality
-0.281.53-0.310.490.26
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.460.440.430.560.62
Intangibles to total assets
0.030.030.030.030.03
Capex to operating cash flow
-4.670.77-4.761.351.6
Capex to revenue
-0.13-0.16-0.19-0.25-0.24
Capex to depreciation
-2.03-2.78-3.77-3.53-3.22
Stock based compensation to revenue
0.230.210.190.230.32
Graham number
4.025.015.217.779.39
ROIC
-0.01-0.02-0.02-0.05-0.07
Return on tangible assets
-0.01-0.02-0.02-0.04-0.07
Graham Net
4.514.464.293.823.29
Working capital
644.05M643.73M637.23M602.89M548.32M
Tangible asset value
753.38M769.67M787.66M777.41M754.88M
Net current asset value
564.18M553.75M546.33M500.77M448.16M
Invested capital
0.090.10.10.130.13
Average receivables
68.1M77.48M80.89M76.53M76.37M
Average payables
17.57M18M18.15M18.96M22.84M
Average inventory
53.89M57.42M61.83M63.7M67.17M
Days sales outstanding
46.3756.3453.4660.1559.84
Days payables outstanding
296.362.5456.5866.9686.84
Days of inventory on hand
807.29187.73195.56225.01229.5
Receivables turnover
1.941.61.681.51.5
Payables turnover
0.31.441.591.341.04
Inventory turnover
0.110.480.460.40.39
ROE
-0.01-0.02-0.02-0.05-0.08
Capex per share
-0.13-0.18-0.25-0.25-0.24

Frequently Asked Questions

What is 10x Genomics, Inc. stock symbol ?

10x Genomics, Inc. is a US stock , located in Pleasanton of California and trading under the symbol TXG

What is 10x Genomics, Inc. stock quote today ?

10x Genomics, Inc. stock price is $28.44 today.

Is 10x Genomics, Inc. stock public?

Yes, 10x Genomics, Inc. is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap